Active substanceFonorucetamFonorucetam Similar drugsTo uncover Slim Story Prof pills inwards Teva Pharmaceutical Enterprises Co., Ltd. Israel Phenotropil® pills inwards VALENTA PHARM, PAO Russia Fonorucetam pills inwards Life Sainses OHCF Russia Dosage form: & nbspPills. Composition:active substance:phenotropyl (N-carbamoylmethyl-4-phenyl-2-pyrrolidone) 50 mg or 100 mg.Excipients:for a dosage of 50 mg: lactose monohydrate - 80,50 mg, potato starch - 18,00 mg, calcium stearate - 1,50 mg.for the dosage of 100 mg: lactose monohydrate - 51.52 mg, potato starch - 46.48 mg, calcium stearate - 2.00 mg. Description:Tablets of flat-cylindrical form from white to white with yellowish or kremovatym a shade of color. Pharmacotherapeutic group:nootropic remedy ATX: & nbspN.06.B.X Other psychostimulants and nootropic drugs Pharmacodynamics:PHENOTROPIL is a nootropic drug, it has a pronounced antiamnestic effect, has a direct activating effect on the integrative activity of the brain, promotes memory consolidation, improves concentration and mental activity, facilitates the learning process, increases the information transfer rate between the cerebral hemispheres, increases the resistance of brain tissue to hypoxia and toxic effects,has anticonvulsant action and anxiolytic activity, regulates the processes of activation and inhibition of the central nervous system, improves mood.PHENOTROPIL has a positive effect on the metabolic processes and blood circulation of the brain, stimulates redox processes, increases the body's energy potential through the utilization of glucose, improves regional blood flow in the ischemic areas of the brain. Increases the content of noradrenaline, dopamine and serotonin in the brain, does not affect the level of GABA, binds neither to GABA nor to GABAA receptors, does not have a significant effect on spontaneous bioelectrical activity of the brain.PHENOTROPIL has no effect on respiration and cardiovascular system, shows an unexpressed diuretic effect, has anorexigenic activity in course use.The stimulating effect of phenotrope is manifested in its ability to exert a moderately pronounced effect on motor reactions, in increasing physical performance, in pronounced antagonism to the catalepytic action of neuroleptics, and in the weakening of the hypnotic effect of ethanol and hexenal.The psycho-stimulating effect of phenothrope prevails in the ideator sphere.Moderate psychostimulant effect of the drug is combined with anxiolytic activity, improves mood, has some analgesic effect, increasing the threshold of pain sensitivity.The adaptogenic effect of phenotrope is manifested in increasing the body's resistance to stress in conditions of excessive mental and physical stress, fatigue, hypokinesia and immobilization, at low temperatures.Against the background of PHENOTROPILA, improvement of vision is noted, which is manifested in an increase in acuity, brightness and visual fields.PHENOTROPIL improves the blood supply of the lower extremities.PHENOTROPIL stimulates the production of antibodies in response to antigen administration, which indicates its immunostimulatory properties, but at the same time it does not promote the development of immediate type hypersensitivity and does not alter the allergic skin inflammatory reaction caused by the introduction of a foreign protein.With the course of the use of phenotrope does not develop drug dependence, tolerance, "withdrawal syndrome."The action of phenothropil is manifested with a single dose, which is important when using the drug in extreme conditions.PHENOTROPIL does not have teratogenic, mutagenic, carcinogenic and embryotoxic properties. Toxicity is low, the lethal dose in an acute experiment is 800 mg / kg. Pharmacokinetics:PHENOTROPIL is rapidly absorbed, penetrates into various organs and tissues, easily passes through the blood-brain barrier. Absolute bioavailability of the drug for oral administration is 100%. The maximum concentration in the blood is reached after 1 hour, the half-life period is 3-5 hours. PHENOTROPIL is not metabolized in the body and is excreted from the body in an unchanged form. Approximately 40% of the drug is excreted in the urine and 60% of the drug is excreted with bile and then. Indications:Diseases of the central nervous system of various genesis, especially those associated with vascular diseases and disorders of metabolic processes in the brain, intoxication (particularly in posttraumatic states and chronic cerebrovascular insufficiency), accompanied by deterioration of intellectual and mnestic functions, decreased motor activity.Neurotic conditions manifested by lethargy, increased exhaustion, decreased psychomotor activity, impaired attention, memory impairment. Violations of learning processes.Depressions of mild and moderate severity.Psychoorganic syndromes, manifested by intellectual-mnestic disorders and apatiko-abulic phenomena, as well as flaccid states in schizophrenia. Convulsive conditions.Obesity (alimentary-constitutional genesis).Prevention of hypoxia, increased resistance to stress, correction of the functional state of the organism in extreme conditions of professional activity in order to prevent the development of fatigue and increase mental and physical performance, correction of daily biorhythm, inversion of the "sleep-wake" cycle; Chronic alcoholism (in order to reduce the phenomena of asthenia, depression, intellectual-mnestic disorders). Contraindications:Individual intolerance. Carefully:PHENOTROPIL is used with caution in patients with severe organic lesions of the liver and kidneys, severe course of arterial hypertension, in patients with atherosclerosis,previously acute panic attacks, acute psychotic conditions that occur with psychomotor agitation - due to the possibility of worsening anxiety, panic, hallucinations and delusions, as well as in patients prone to allergic reactions to nootropic drugs of the pyrrolidone group. Pregnancy and lactation:PHENOTROPIL should not be given during pregnancy and breast-feeding due to lack of clinical research data. Dosing and Administration:PHENOTROPIL is used inside, immediately after a meal. The dose of the drug and the duration of treatment should be determined by the doctor. Doses vary depending on the characteristics of the patient's condition. The average single dose is 150 mg (100 mg to 250 mg); the average daily dose is 250 mg (from 200 mg to 300 mg). The maximum allowable dose is 750 mg per day. It is recommended to divide the daily dose into 2 doses. The daily dose to 100 mg taken once in the morning, and over 100 mg divided daily dose into two divided doses. Duration of treatment can vary from 2 weeks to 3 months. The average duration of treatment is 30 days. If necessary, the course can be repeated in a month.To improve performance - 100-200 mg once in the morning, for 2 weeks (for athletes - 3 days).The recommended duration of treatment for patients with alimentary-constitutional obesity is 30-60 days at a dose of 100-200 mg once a day (in the morning hours). It is not recommended to take FENOTROPIL later than 15 hours. Side effects:Insomnia (in case of taking the drug later than 15 hours). Some patients in the first 1-3 days of taking the drug may experience psychomotor agitation, hyperemia of the skin, a feeling of warmth, an increase in blood pressure. Overdose:There were no cases of overdose.Treatment: symptomatic therapy. Interaction:PHENOTROPIL can enhance the effect of drugs that stimulate the central nervous system, antidepressants and nootropic drugs. Special instructions:With excessive psychoemotional exhaustion in the background of chronic stress and fatigue, chronic insomnia, a single dose, PHENOTROPILA in the first day can cause a sharp need for sleep. Such patients on an outpatient basis should be advised to begin the course of the drug on non-working days.Pediatric UseIt is not recommended the appointment of phenotrope to children, due to the lack of data on the use of the drug in children. Form release / dosage:Tablets, 50 or 100 mg. Packaging:For 10 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil.1 or 3 contour mesh packages together with the instruction for use are placed in a pack of cardboard. Storage conditions:In dry, dark place at a temperature of no higher than 30 ° C.Keep out of the reach of children. Shelf life:5 years. Do not use after the expiration date. Terms of leave from pharmacies:On prescription Registration number:P N002784 / 01 Date of registration:08.04.2009 The owner of the registration certificate:VALENTA PHARM, PAO VALENTA PHARM, PAO Russia Manufacturer: & nbspVALENTA PHARMACEUTICS, JSC Russia Representation: & nbspVALENTA PHARM, PAO VALENTA PHARM, PAO Russia Information update date: & nbsp01.06.2015 Illustrated instructions × Illustrated instructions Instructions